Robert Siegel

Title: The Innovations of Robert Siegel

Introduction

Robert Siegel is a notable inventor based in San Diego, California. He has made significant contributions to the field of biotechnology, particularly in the area of neuronal nicotinic acetylcholine receptors. His work has implications for understanding various neurological functions and disorders.

Latest Patents

Robert Siegel holds a patent titled "DNA Encoding Human α and β Subunits of Neuronal Nicotinic Acetylcholine Receptor, Cells Transformed Therewith, and Recombinant Cell Line Expressing a Human α and β Subunit of Neuronal Nicotinic Acetylcholine Receptor." This patent involves isolated nucleic acid molecules, specifically DNA or RNA that encodes the human neuronal nicotinic acetylcholine receptor alpha and beta subunits. The patent also covers mammalian and amphibian cells containing this DNA, as well as methods for producing the α and β subunits. Additionally, it describes a recombinant, non-human cell line that expresses the human α subunit of nAChR.

Career Highlights

Robert Siegel is currently associated with Merck & Co., Inc., a leading global healthcare company. His work at Merck has allowed him to further his research and development in the field of neuroscience and pharmacology.

Collaborations

Throughout his career, Robert has collaborated with several talented individuals, including Kathryn J Elliott and Allison Gillespie. These collaborations have contributed to the advancement of his research and the successful development of innovative solutions in his field.

Conclusion

Robert Siegel's contributions to the field of biotechnology, particularly through his patent on neuronal nicotinic acetylcholine receptors, highlight his role as an influential inventor. His work continues to impact the scientific community and advance our understanding of neurological functions.